Lotiglipron
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Pfizer · Phase 2 · Terminated · Enrollment 902
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| PF-07081532 20 mg T2DM | n/r | n/r | n/r | n/r |
| PF-07081532 40 mg T2DM | n/r | n/r | n/r | n/r |
| PF-07081532 80 mg T2DM | n/r | n/r | n/r | n/r |
| PF-07081532 160 mg T2DM | n/r | n/r | n/r | n/r |
| PF-07081532 260 mg T2DM | n/r | n/r | n/r | n/r |
| Placebo T2DM | n/r | n/r | n/r | n/r |
| PF-07081532 80 mg Obesity | n/r | n/r | n/r | n/r |
| PF-07081532 140 mg Obesity | n/r | n/r | n/r | n/r |
| PF-07081532 200 mg Obesity (Option 1) | n/r | n/r | n/r | n/r |
| PF-07081532 200 mg Obesity (Option 2) | n/r | n/r | n/r | n/r |
| PF-07081532 260 mg Obesity | n/r | n/r | n/r | n/r |
| Rybelsus 14 mg T2DM | n/r | n/r | n/r | n/r |
| Placebo Obesity | n/r | n/r | n/r | n/r |
Not shown
- PF-07081532 20 mg T2DM: endpoint not reported
- PF-07081532 40 mg T2DM: endpoint not reported
- PF-07081532 80 mg T2DM: endpoint not reported
- PF-07081532 160 mg T2DM: endpoint not reported
- PF-07081532 260 mg T2DM: endpoint not reported
- Placebo T2DM: endpoint not reported
- PF-07081532 80 mg Obesity: endpoint not reported
- PF-07081532 140 mg Obesity: endpoint not reported
- PF-07081532 200 mg Obesity (Option 1): endpoint not reported
- PF-07081532 200 mg Obesity (Option 2): endpoint not reported
- PF-07081532 260 mg Obesity: endpoint not reported
- Rybelsus 14 mg T2DM: endpoint not reported
- Placebo Obesity: endpoint not reported